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Background: Esophageal squamous cell carcinoma is one of the most common malignancies in the world. Studies
have confirmed that there are many genes abnormally hypermethylated in esophageal squamous cell carcinoma. The
objective is to detect methylation of the RASSF1A gene promoter and the expression of the DNA methyltransferase 1
(DNMT1) protein in esophageal cancer tissue and discuss their relationship with esophageal squamous cell carcinoma.
Methods: The CpG island methylation status of RASSF1A genes were analyzed in 100 cases of tumor specimens as
well as their adjacent tissues which was used for methylation-specific polymerase chain reaction (MSP). The expression
of DNMT1 protein was determined by immunohistochemistry. Difference between measurement data and categorical
data was compared through analysis of t test and chi-square test. All the statistics were taken with a bilateral test. The
difference was statistically significant (P < 0.05).
Results: The promoter methylation of the RASSF1A gene promoter has been detected in 45 out of 100 (45%)
esophageal squamous carcinoma cases, while methylation of RASSF1A gene has been detected in 2 out of 100
adjacent normal tissues (2%). The RASSF1A gene promoter was highly methylated in cancer tissues, and there were
significant differences between normal esophagus tissues and esophageal squamous carcinoma (P < 0.05). The
expression of DNMT1 protein has been detected in 61 out of 100 (61%) esophageal squamous carcinoma cases,
including 41 cases in the above 45 methylated samples of RASSF1A gene promoter, and none in adjacent tissues.
DNMT1 proteins are highly expressed in cancer tissues, and there were significant differences (P < 0.05). In positive
cases for methylation of RASSF1A, the DNMT1 protein had been detected in 41 out of 45 (91%), while in
non-methylated cancer cases, 20 out of 55(36.3%), and the difference is significant (P < 0.05).
Conclusions: Esophageal squamous carcinoma tumorigenesis may be related with hypermethylation of DNMT1 and
RASSF1A promoter CpG island due to their high expression and also their hypermethylation.
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Esophageal squamous cell carcinoma is one of the most
common malignancies in the world. As a whole, China is
considered as the highest incidence country in the world
with esophageal squamous cell carcinoma rates being the
fourth to sixth of the total malignancies and the second to
third of those in the digestive system in China, and it has
seriously affected our people’s safety and health [1].The risk
factors of esophageal squamous cell carcinoma include* Correspondence: guilinsjf@163.com
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unless otherwise stated.chronic nitrosamines stimulation, Western diet(low-fiber,
high-fat diet), family history, inflammation and trauma,
obesity, and inflammatory esophageal diseases. Studies
have confirmed that there are many genes abnormally
hypermethylated in esophageal squamous cell carcinoma
[2,3]. In order to find new a diagnostic molecular marker
in esophageal squamous cell carcinoma, this study focuses
on the expression of the key enzyme in the process of
DNA methylation - DNA methyltransferase 1 (DNMT1) -
in esophageal squamous cell carcinoma tissues and the re-
lationship with the promoter methylation status of CpG
island in RASSF1A.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The clinicopathologic data
With the informed consent of all patients and approval
of the ethics committee, tumor tissues were obtained
during surgery, and the diagnosis of esophageal squa-
mous cell carcinomas was confirmed by HE staining
from 100 patients at the affiliated Hospital of Guilin
Medical College from 2002 to 2012 (The affiliated hos-
pital of Guilin medical University ethics committee gives
approval to this study). Clinical-pathological features are
shown in Table 1. No patients had received preoperative
chemotherapy, radiation therapy, or other biological
therapy. The clinical records and pathological data were
of good integrity (Table 1).
Main reagents
The main reagents were the DNA rapid extraction kit
from Aidlab Biotechnologies Co., Ltd. (Haidan District,
Beijing), the EZ Bisulfite DNA Clean-up Kit from
Aidlab Biotechnologies Co., Ltd. (Haidan District,
Beijing), the PCR Amplification Kit from Aidlab
Biotechnologies Co., Ltd. (Haidan District, Beijing), and
the DNMT1 Monoclonal Antibody from (Sigma-Aldrich,
Shanghai, China).
MSP
Genomic DNA (1 μg) was harvested with a DNA rapid
extraction kit for bisulfite modification with the CpGTable 1 Clinical-pathologic profiles of the esophageal
squamous cell carcinoma cases in this study
Clinical-pathologic features Number of cases
Gender Male 72
Female 28
Age (year) Median 63.4
Range 42 to 74
Tumor site Upper 12
Midpiece 74
Lower 14
Histological types Squamous cell carcinoma 100
Differentiation Moderate 82
Poor 18
Follow-up 27 (3 years) Survival 86
Deceased 14






TNM, tumor node metastasis.genome kit according to the manufacturer’s instructions;
5 μL of bisulfite-modified DNA was used per 25 μL
methylation-specific PCR (MSP) reaction. For PCR,
methylated (M) and unmethylated (U) primer pairs were
initially denatured at 94°C for 3 min followed by 35 cy-
cles with a 1-min denaturation step, 30 s of annealing at
60°C( demethylation 58°C), and 3 min of extension at
72°C. Final extension after 35 cycles was at 72°C for
10 min, and the product was stored at 4°C. PCR products
were analyzed by agarose gel electrophoresis and ethidium
bromide staining, and the objective gene stripes were used
as the positive expression. RASSF1A-U used the
methylation-specific primers 5′-AACATAACCCAATTAA
ACCCATACTTC-3′(sense)and 5′-GGGGTTTGTTTTG
TGGTTTTGTTT-3′(antisense) (product length 105 bp)
and RASSF1A-M using the unmethylation-specific primers
5′-GGGTTCGTTTTGTGGTTTCGTTC-3′(sense)and
5′-TAACCCGATTAAACCCGTACTTCG-3′(antisense)
(product length 105 bp), plus 100 ng of bisulfite-
modified DNA.
Immunohistochemistry analysis
All of the tissues were fixed in 10% neutral formalin, em-
bedded in paraffin, and serial sectioned into 4 μm. The
antibody dilution ratio is 1:200. Using the known positive
section as the positive criteria, PBS displaces the primary
antibody as the negative criteria. The immunostaining was
performed with the antibody using DAKO Envision sys-
tem/3,3-diaminoben-aidine (DAB) staining. The result was
scored by conjunction with both staining intensity and the
percentage of positive staining cells. To identify the IHC, all
the made tissue sections were stained with H&E and
double blind was used in the experiment. Each section was
reviewed by two pathologists independently, and the results
were reconfirmed once inconsistent. Semi-quantitative inte-
gral analyses were used to estimate the results, and each
sample was given an intensity score (0 to 3) and a percent-
age of cell positive score (0 = less than 5%, 1 = 6% to 25%,
2 = 26% to 50%, 3 = 51% to 75%, 4 =more than 75%).An
overall immunohistochemistry score was calculated by
multiplying the intensity and percentage of cell positive
scores. Canary yellow colors were handled as 1 point, clay-
bank as 2 points, and brown as 3 points. Scores of 0 were
recorded as negative, 1 to 4 as weakly positive (+), 6 to 8 as
positive (++), and 9 to 12 as strongly positive (+++). Fur-
thermore, we counted the negative and weakly positive as
‘negative’ and the positive and strongly positive as ‘positive’.
Results
The comparison of promoter methylation of RASSF1A
gene between esophageal carcinoma tissues and the
para-cancerous tissues
Among the 100 patients, the promoter methylation of
RASSF1A gene (overall or partly) was found in 45
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RASSF1A gene was also detected in adjacent normal tis-
sues (2%). The RASSF1A gene promoter was highly
methylated in cancer tissues, and there were significant
differences between normal esophagus tissues and
esophageal squamous carcinoma (P < 0.05) (Figure 1A).The different expression of DNMT1 in normal esophagus
tissues and esophageal squamous carcinoma was
detected by immunohistochemistry
The express of DNMT1 protein has been detected in 61
out of 100 (61%) esophageal squamous carcinoma cases
and none in adjacent tissues. Among the 45 cases whose
RASSF1A gene promoter CpG island methylation or
partial methylation was detected in the MSP experi-
ments, it was found that DNMT1 was expressed posi-
tively in 41 cases. DNMT1 proteins are highly expressed
in cancer tissues, and there were significant differences
(P < 0.05) (Figure 1B,C,D).Figure 1 Representative MSP results in tumor tissues and the expressio
(A) Representative MSP results in tumor tissues: 1, 2, 3, 4, 5, and 6 for tumor ti
positive control; 4, 5, and 6 embodied hypermethylation and was the methyla
methylation. (B-D) The expression of DNMT1 protein in esophageal squamou
(B)Weakly positive; (C) positive strongly positive; (E) normal esophageal tissueThe relationship between the promoter methylation of
RASSF1A gene and the expression of DNMT1 protein in
esophageal squamous carcinoma
In the CpG-island-methylated esophageal squamous car-
cinoma cases, the DNMT1 protein has been detected in
41 out of 45 (91%), while in non-methylated cancer
cases, 20 out of 55(36.3%), and the difference is signifi-
cant (P < 0.05) (Table 2).
Discussion
As a new tumor suppressor gene, RASSF1A gene was
cloned from the three short arms of a chromosome (3
p21. 3) in 2000, and it is located at 3 p21. 3 on a 120-
kb-long minimum homozygous loss zone. Because of the
differences between alternative splicing and promoter, it
formed three main transcripts, called A, B, and C. The
cDNA’s length of RASSF1A gene was 1,837 bp, including
the open reading frame encoding formed by 340 amino
acids which consisted of six exons together in sequence.
The protein weight by RASSF1A gene transcription wasn of DNMT1 protein in esophageal squamous carcinoma tissue.
ssues; 1 and 2 represented unmethylation which was the demethylation
tion positive control. IVD, in vitro DNA methylation; u, unmethylation; m,
s carcinoma tissue by immunohistochemistry results (SP× 400).
, negative control.
Table 2 Relationship between promoter methylation of
RASSF1A gene and expression of DNMT1 protein in
esophageal squamous carcinoma





(total contained in *)
4 45 91
Demethylation 20 35 55 36.3
Total 61 39 100 61
*Represents the 45 cases of promoter methylation of RASSF1A gene.
Du et al. World Journal of Surgical Oncology  (2015) 13:141 Page 4 of 538.8 kD, whose N-terminal binding area with diacylglyc-
erol and phorbol esters was highly homologous. The N-
terminal binding area is also regarded as the conservative
area of the protein kinase C, and the C-terminal of the
protein originated same as with the Ras-effecting protein
Nore1 and rat Maxp1 of the mouse. The RASSF1A gene
can regulate cell proliferation and apoptosis by inhibiting
the Ras/RASSF1/ERK signal transduction pathways, as
well as maintain the stability of microtubules [4]. Previous
studies have reported the involvement of RASSF1A pro-
moter methylation in several cancers, including prostate
[5], ovarian [6], endometrial [7], gastric [8], lung [9], and
breast cancer [10]. And, it has been generally accepted
that the hypermethylated status of the promoter CpG
islands represents the long-term transcription-silencing
state of the genes [11-13].Other researches have also of-
fered the evidence that RASSF1 stimulation of lung cancer
cell proliferation depends on IGFBP-5 and PIWIL1
expression levels [14].
In this research, we found that the RASSF1A gene pro-
moter was highly methylated in cancer tissues, and there
were significant differences between normal esophagus tis-
sues and esophageal squamous carcinoma. It was conjec-
tured that the promoter CpG island hypermethylation of
RASSF1A in human esophageal squamous carcinoma
plays a powerful role in the inactivation and transcrip-
tional gene silencing of the RASSF1A gene. But it does
not exist in esophageal RASSF1A promoter methylation,
and the gene expressed negatively in several patients with
the possible mutual adjustment of a bit of a mutation and
loss of heterozygosity.
Not only did we focus on the status of RASSF1A methy-
lation, but we also explored its possible mechanism pre-
liminarily. As one member of DNMTs’ family, DNMT1
has the close relationship with gene methylation in the
present study, which can maintain the gene’s methylation.
DNMT1 is the predominant methyltransferase, function-
ing primarily to maintain DNA methylation patterns after
DNA replication. Research [15] has shown that the ex-
pression DNMT1 was high in human esophageal squa-
mous carcinoma, suggesting that DNMT1 could regulatethe key gene’s function abnormally in human esophageal
squamous carcinoma. DNMT1 expression abnormalities
may be involved in the process of esophageal cancer, but
the development in the majority of esophageal cancers is
related to multiple factors, genes, and multiple-step pro-
cesses. Its pathogenesis is very complex and not yet clear.
Additional studies [16] have demonstrated that DNMT3b
is also expressed in healthy tissues, albeit at levels consid-
erably lower than DNMT1, and function primarily in de
novo methylation. Specific inhibition of DNMT1 or
DNMT3b expression promotes growth arrest in cancer
cells and attests to the relevance of DNMT expression-
activity during malignant transformation [16]. DNMT3b
may participate in gene methylation in multiple tumors,
which can be used as early biomarkers in the early diagno-
sis of a tumor [16]. Results of our studies clearly indicate
that the DNMT1 protein is highly expressed in cancer tis-
sues, and there were significant differences. And further-
more, we also found that in the positive cases for
methylation of RASSF1A, the DNMT1 protein had over-
expressed in non-methylated cancer cases with significant
difference (41 DNMT1 positive cases in 45 RASSF1A
positive cases). With the comprehensive results above, we
could presume that DNMT1 high expression in esopha-
geal cancer tissues could lead to high methylation in
RASSF1A gene promoter CpG island. This is only a pre-
liminary speculation of this experiment; its reason and
mechanism is not clear and further investigation is ex-
pected. DNMT1 and RASSF1A gene high expression in
cancer patients, perhaps, can be used as a tumor marker
for the early diagnosis of tumors [17].
Esophageal carcinoma is the eighth most common cancer
in the world and the seventh leading cause of cancer death
worldwide [18]. Although surgical treatment to esophageal
cancer is the main method currently, early diagnosis and
operation is the keystone in reducing the mortality of
esophageal cancer. Epigenetics may play an important role
in tumor diagnosis and treatment gradually.
Conclusion
In conclusion, the high expression of DNMT1 in
esophageal cancer compared with normal tissue prob-
ably reflects the increased methylation of RASSF1A gene
promoter CpG island. And, the expression quantity of
DNMT1 increased accompanied with the elevating de-
gree of its hypermethylation. DNA methylation is one of
the important contents in epigenetics research, and it is
closely related to the occurrence and the development of
various tumors with tissue specificity. On the basis of
prophase studies, future research should peg where cer-
tain methylation differences are associated with esopha-
geal cancer, establish the esophageal-cancer-related gene
methylation spectrum, and focus on DNMT’s family
roles and specific mechanisms. Thus, we could provide
Du et al. World Journal of Surgical Oncology  (2015) 13:141 Page 5 of 5epigenetics theoretical basis of the diagnosis and treat-
ment for esophageal squamous carcinoma.
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